ObjectiveTo investigate the mechanism of lignans-1inhibiting the proliferation of human gastric cancer cell line SGC-7901. MethodsThe morphological changes of the cells were observed by the inverted phase contrast microscope. The cell surviving ratio was determined by methylthiazoly tetrazolium (MTT) assay after lignans-1 added to the cells at different concentrations on human gastric cancer SGC-7901 cell line in vitro, and half maximal (50%) inhibitory concentration (IC50) values were calculated. The cell cycle phase distribution and apoptosis were measured by flow cytometry. The expressions of apoptosis associated proteins of Caspase3, Bcl-2 and Bax were determined by Western blot. ResultsMorphological examination showed that lignans-1 could destroy the SGC-7901 cells with the increasing concentration of lignans-1. The inhibitory effect of lignans-1 on SGC-7901 cell was associated with time-and dose-dependent manner at the different concentration (2.5-20 μg/mL), P < 0.05. The IC50 of lignans-1 on the SGC-7901 cells was 4.19 μg/mL. The rate of the apoptosis cells and G2/M phase cells raised significantly after 48 hours' treatment with lignans-1, as same as the expression of Caspase3 and Bax (P < 0.05). G0/G1 phase cells and Bcl-2 decreased significantly with the increasing concentration of lignans-1 (P < 0.05). ConclusionsThe lignans-1 could inhibit the proliferation of SGC-7901 cells and induce apoptosis by arresting cells at G2/M phase in vitro. The mechanism is associated with activation of Caspase3 and Bax and inhibition of Bcl-2.
ObjectiveTo investigate therapeutic method, curative effect, and prognosis of inferior vena cava (IVC) blocking Budd-Chiari syndrome (BCS) with thrombosis. MethodsClinical data of 128 BCS patients with membranous or short-segment occlusion of IVC as well as IVC thrombosis, who accepted interventional treatment in The Affiliated Hospital of Zhengzhou University from Apr. 2004 to Jun. 2012, were retrospectively analyzed. Comparison of the difference on effect indicators between predilation group and stent filter group was performed. ResultsThereinto, 9 patients with fresh IVC thrombosis were treated with agitation thrombolysis (agitation thrombolysis group), 56 patients were predilated by small balloon (predilation group), for the rest 63 patients, a stent filter was deployed (stent filter group). Besides 1 stent filter fractured during the first removal attempt and had to be extracted surgically in the stent filter group (patients suffered with sent migration), in addition, the surgeries of other patients were technically successful without procedure-related complication. effect indicators were satisfactory in all patients, and there were no statistical differences between predilation group and stent filter group in dosage of urokinase, urokinase thrombolysis time, hospital stay, and incidence of complication (P > 0.05), but the cost of predilation group was lower than that of stent filter group (P < 0.01). All of the 128 patients were followed-up postoperation, and the duration range from 18 to 66 months with an average of 44.2 months. During the follow-up period, reobstruction of the IVC was observed in 13 patients without thrombosis, of which 1 patient in agitation thrombolysis group, 6 patients in predilation group, and 6 patients in stent filter group. There was no significant difference in recurrence rate between predilation group and stent filter group (P > 0.05). Patients with recurrence got re-expansion treatment, and no stenosis or thrombogenesis recurred. ConclusionsAgitation thrombolysis for fresh IVC trombosis in the patients with BCS is safe and effective. Predilation and stent filter techniques are all effective in the treatment of BCS with chronic IVC thrombosis, but the former technique seems to be more economic.